Adult Clinical Trials

Sarcomas- Cancers of the bones and soft body tissues

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact the Sarcoma Clinical Trials Office at 919.681.4768.

8 trials identified.

AEWS1031 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Purpose: This randomized phase III trial studies combination chemotherapy to see how well it works compared to combination chemotherapy with topotecan hydrochloride in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, etoposide, and topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with topotecan hydrochloride in treating Ewing sarcoma.
Reference Number: 00028814
View this trial at ClinicalTrials.gov

A Phase 1B Dose-Escalation and Phase 2A Study of TRC105 in Combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Richard Riedel
Contact: Sarcoma Oncology Research Office
Phone: 919.681.4768
Purpose: The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma. Up to 18 patients will be treated. The purpose of the phase 2 portion is to estimate the PFS of patients with advanced soft tissue sarcoma by RECIST 1.1 and estimate ORR in a separate cohort of patients with angiosarcoma by RECIST 1.1. Up to 76 patients will be treated in phase 2, including a cohort of up to 13 patients with angiosarcoma.
Reference Number: 00050117
View this trial at ClinicalTrials.gov

SARC024: A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcomas
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Richard Riedel
Contact: Sarcoma Oncology Clinical Trials Office
Phone: 919.681.4768
Purpose: Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma. Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing/Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents.
Reference Number: 00052320
View this trial at ClinicalTrials.gov

ARST1321 Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Purpose: This randomized phase II/III trial studies how well pazopanib hydrochloride, combination chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in combination with pazopanib hydrochloride or combination chemotherapy in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy works better when given with or without combination chemotherapy and/or pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.
Reference Number: 00056072
View this trial at ClinicalTrials.gov

A Phase 2 Multi-Center Investigation of Efficacy of ABI-009 (nab-rapamycin) in Patients with Advanced Malignant Perivascular Epithelioid Tumors (PEComa)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Richard Riedel
Contact: Sarcoma Oncology Clinical Trials Office
Phone: 919.681.1883
Purpose: A phase 2 multi-center investigation of efficacy of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa)
Reference Number: 00067600
View this trial at ClinicalTrials.gov

Alliance A091304: A Phase I/Randomized Phase II Study of MLN0128 versus Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma
Phase: Phase I
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Sarcoma Oncology Clinical Trials Office
Phone: 919.681.1883
Purpose: This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride both work to stop the growth of tumor cells by blocking enzymes that are needed for cell growth. It is not yet known whether sapanisertib may be more effective than standard treatment with pazopanib hydrochloride in treating patients with locally advanced or metastatic sarcoma.
Reference Number: 00069057
View this trial at ClinicalTrials.gov

A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Richard Riedel
Contact: Sarcoma Oncology Clinical Trials Office
Phone: 919.681.1883
Purpose: This is an open-label Phase 2 randomized study that will examine the use of the study agents, CMB305 (sequentially administered LV305 [a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene] and G305 [NY-ESO-1 recombinant protein plus GLA-SE]) in combination with atezolizumab or atezolizumab alone, in patients with locally advanced, relapsed or metastatic sarcoma (synovial or myxoid/round cell liposarcoma) expressing the NY-ESO-1 protein. CMB305 is a novel approach designed to stimulate the body's immune system to fight the spread and growth of cancer in patients whose tumors express the NY-ESO-1 protein. LV305 will be given in a prime-boost approach with G305 to induce a potentially synergistic immunotherapeutic response in combination with atezolizumab.
Reference Number: 00069932
View this trial at ClinicalTrials.gov

A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Richard Riedel
Contact: SARCOMA Clinical Trials Research Office
Phone: 919.681.1883
Purpose: This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 245 total patients will be randomized to study treatment (selinexor or placebo).
Reference Number: 00072155
View this trial at ClinicalTrials.gov